$NVO is still the core name in weight-loss and diabetes drugs. - Q2 sales were DKK 78.5B$ - adjusted sales rose 7% - first-half sales reached DKK 175B$, up 18%

$NVO is still the core name in weight-loss and diabetes drugs. - Q2 sales were DKK 78.5B$ - adjusted sales rose 7% - first-half sales reached DKK 175B$, up 18% at constant exchange rates - Wegovy and Ozempic kept selling That business has the stock sitting inside 54-30.25$ From here the mapped ta…